Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

730 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay.
Powles T, Young A, Nimeiri H, Madison RW, Fine A, Zollinger DR, Huang Y, Xu C, Gjoerup OV, Aushev VN, Wu HT, Aleshin A, Carter C, Davarpanah N, Degaonkar V, Gupta P, Mariathasan S, Schleifman E, Assaf ZJ, Oxnard G, Hegde PS. Powles T, et al. Among authors: fine a. Front Oncol. 2023 Jul 31;13:1221718. doi: 10.3389/fonc.2023.1221718. eCollection 2023. Front Oncol. 2023. PMID: 37601688 Free PMC article.
Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection.
Lonardi S, Nimeiri H, Xu C, Zollinger DR, Madison RW, Fine AD, Gjoerup O, Rasola C, Angerilli V, Sharma S, Wu HT, Palsuledesai CC, Malhotra M, Aleshin A, Loupakis F, Renkonen E, Hegde P, Fassan M. Lonardi S, et al. Among authors: fine ad. Int J Mol Sci. 2022 Sep 29;23(19):11529. doi: 10.3390/ijms231911529. Int J Mol Sci. 2022. PMID: 36232827 Free PMC article.
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Vega DM, Nishimura KK, Zariffa N, Thompson JC, Hoering A, Cilento V, Rosenthal A, Anagnostou V, Baden J, Beaver JA, Chaudhuri AA, Chudova D, Fine AD, Fiore J, Hodge R, Hodgson D, Hunkapiller N, Klass DM, Kobie J, Peña C, Pennello G, Peterman N, Philip R, Quinn KJ, Raben D, Rosner GL, Sausen M, Tezcan A, Xia Q, Yi J, Young AG, Stewart MD, Carpenter EL, Aggarwal C, Allen J. Vega DM, et al. Among authors: fine ad. JCO Precis Oncol. 2022 Aug;6:e2100372. doi: 10.1200/PO.21.00372. JCO Precis Oncol. 2022. PMID: 35952319 Free PMC article.
Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC.
Schwartzberg LS, Li G, Tolba K, Bourla AB, Schulze K, Gadgil R, Fine A, Lofgren KT, Graf RP, Oxnard GR, Daniel D. Schwartzberg LS, et al. Among authors: fine a. JTO Clin Res Rep. 2022 Aug 2;3(9):100386. doi: 10.1016/j.jtocrr.2022.100386. eCollection 2022 Sep. JTO Clin Res Rep. 2022. PMID: 36089920 Free PMC article.
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.
Assaf ZJF, Zou W, Fine AD, Socinski MA, Young A, Lipson D, Freidin JF, Kennedy M, Polisecki E, Nishio M, Fabrizio D, Oxnard GR, Cummings C, Rode A, Reck M, Patil NS, Lee M, Shames DS, Schulze K. Assaf ZJF, et al. Among authors: fine ad. Nat Med. 2023 Apr;29(4):859-868. doi: 10.1038/s41591-023-02226-6. Epub 2023 Mar 16. Nat Med. 2023. PMID: 36928816 Free PMC article.
730 results